Company News • Endpoint Arena

News Updates

Tue, May 26, 2026

1 updates

1:15 AM

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

Basel, May 26, 2026 – Novartis will present data from 15 abstracts from its kidney portfolio at this year’s European Renal Association (ERA) Congress in Glasgow, June 3-6. The presentations reinforce our ambition to advance scientific understanding across progressive immune-mediated kidney diseases and support the evolution of kidney care.

Presentation / Abstract • Phase 3ERA Late-breaker oral presentation Thu, Jun 4, 2026, 12:30 PM BSTnovartis.com

Thu, May 21, 2026

1 updates

1:15 AM

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

Basel, May 21, 2026 – Novartis will present data from more than 65 company or investigator sponsored abstracts at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting and the European Hematology Association (EHA) 2026 Congress.

Presentation / Abstract • Phase 3ASCO oral presentation Sat, May 30, 2026, 1:15 PM CDTnovartis.com

Sun, May 17, 2026

1 updates

3:30 PM

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

Basel, May 17, 2026 – Novartis today announced new data from PSMAddition demonstrating improved prostate-specific antigen (PSA) responses with Pluvicto ® (lutetium (177Lu) vipivotide tetraxetan) combined with standard of care (SoC) in PSMA-positive metastatic hormone sensitive prostate cancer (mHSPC)....

Presentation / Abstract • Phase 3AUA rapid oral presentation Sun, May 17, 2026novartis.com

Thu, May 7, 2026

1 updates

9:00 AM

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

Basel, May 7, 2026 – Novartis, a leading global innovative medicines company, today broke ground on its new 46,000 sq. ft radioligand therapy (RLT) manufacturing site in Denton, Texas, the latest milestone in its broader $23 billion investment in US manufacturing and research....

novartis.com

Thu, Apr 30, 2026

1 updates

7:00 AM

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

Basel, April 30, 2026 – Novartis today announced plans to add a new facility in Morrisville, North Carolina, focused on active pharmaceutical ingredient (API) manufacturing for solid dosage tablets, capsules and RNA therapeutics....

novartis.com

Tue, Apr 28, 2026

1 updates

1:00 AM

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

Ad hoc announcement pursuant to Art. 53 LR First quarter

novartis.com

Mon, Apr 27, 2026

1 updates

1:15 AM

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

Basel, April 27, 2026 – Novartis announced today that the European Commission (EC) approved Rhapsido ® (remibrutinib) for chronic spontaneous urticaria (CSU) in adult patients with inadequate response to H1-antihistamine treatment....

novartis.com

Fri, Apr 24, 2026

2 updates

6:30 AM

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

Basel, April 24, 2026 – Novartis today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for Itvisma ® (intrathecal onasemnogene abeparvovec)....

novartis.com

1:15 AM

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

Basel, April 24, 2026 – Novartis today announced that the World Health Organization (WHO) has prequalified Coartem® (artemether-lumefantrine) Baby, the first and only antimalarial developed specifically for newborns and young infants weighing from 2 to 5 kilograms....

novartis.com

Thu, Apr 9, 2026

1 updates

1:15 AM

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

Basel, April 9, 2026 – Novartis today announced the expansion of its programs to find and treat patients with heart disease and cancer in hard-to-reach communities around the world. This comes as public health efforts against chronic diseases slow or reverse in many countries....

novartis.com

Sun, Mar 29, 2026

1 updates

1:15 AM

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

Basel, March 29, 2026 – Novartis today announced final two-year results from the Phase III APPLAUSE‑IgAN study of Fabhalta ® (iptacopan) in IgA nephropathy (IgAN). Fabhalta demonstrated a statistically significant, clinically meaningful improvement in estimated glomerular filtration rate (eGFR) slope, a key marker of kidney function, compared with placebo 1...

Trial Results • Phase 3novartis.com

Fri, Mar 27, 2026

1 updates

2:00 AM

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

- Proposed acquisition strengthens Novartis immunology strategy in food allergy and other IgE-driven diseases - Lead asset Exl-111 builds on proven IgE biology with a differentiated mechanism designed to dissociate receptor-bound IgE and drive faster, deeper pathway suppression - Exl-111 would complement existing Novartis portfolio in allergy with potential...

novartis.com

Mon, Mar 23, 2026

1 updates

2:15 AM

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

Basel, March 23, 2026 – Novartis will present data from more than 20 abstracts from its growing immunology portfolio at this year’s American Academy of Dermatology (AAD) Annual Meeting.

Presentation / Abstract • Phase 3novartis.com

Fri, Mar 20, 2026

1 updates

2:00 AM

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

Basel, March 20, 2026 – Novartis today announced that it has entered into an agreement with Synnovation Therapeutics, LLC to acquire SNV4818, a pan-mutant‑selective PI3Kα inhibitor, exploring a next-generation approach for the treatment of patients with HR+/HER2- breast cancer and potentially other solid tumor indications.

novartis.com

Fri, Mar 13, 2026

1 updates

1:35 PM

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

Basel, March 13, 2026 – Novartis announced today that Cosentyx ® (secukinumab) received US Food and Drug Administration (FDA) approval for treating pediatric patients 12 years and older with moderate to severe hidradenitis suppurativa (HS), making it the only IL-17A inhibitor for this population 1 ....

novartis.com

Fri, Mar 6, 2026

1 updates

8:24 AM

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

Basel, March 6, 2026 – Novartis shareholders today agreed to the Board of Directors’ recommendations for all proposed resolutions at the company’s Annual General Meeting (AGM). A total of 1 554 shareholders were present at the meeting held in Basel, representing approximately 59.15% of the issued shares of Novartis....

novartis.com